Anti-TNF therapy in rheumatoid arthritis;Place des therapeutiques anti-TNF dans la polyarthrite rhumatoide

Presse Medicale

Volumn 29, Issue 9, 2000, Pages 463-468

  Meyer, O ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LENERCEPT; MESSENGER RNA; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; SALAZOSULFAPYRIDINE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; IMMUNOCYTOCHEMISTRY; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TRANSGENIC MOUSE; ADULT; ANIMAL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DBA MOUSE; DRUG ANTAGONISM; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MOUSE; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GAMMA-CHAINS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MICE; MICE, INBRED DBA; MICE, TRANSGENIC; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFASALAZINE; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034635850     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997 ; 40:598-609.
2. Thomas R, Lipsky PE. Presentation of self peptides by dendritic cells. Possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum 1996 ; 36:183-90.
3. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononudear phagocytes and rheumatoid synovitis. Arthritis Rheum 1997 ; 40:15-18.
4. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors ? Arthritis Rheum 1996 ; 39:1781-90.
5. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor ain rheumatoid arthritis. Arthritis Rheum 1995 ; 38:151-60.
6. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996 ; 14:397-440.
7. Dayer JM, Fenner H. The role of cytokines and their inhibitors in arthritis. Baillières Clinical Rheum 1992 ; 6:485-517.
8. Miossec P. Cytokine abnormalities in inflammatory arthritis. Baillière's Clim Rheum 1992 ; 8:373-92.
9. Moreland LW, Heck LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum 1997 ; 40:397-409.
10. e symposium International d'Immuno-Rhumatologie, J Clot et J Sany, Montpellier 1995, éditions de l'interligne.
11. Kavanaugh AF Anti-tumor necrosis factor α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis in North America 1998 ; 24:593-614.
12. Cope AP, Londei M, Chu NR et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994 ; 94:749-60.
13. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Current Opinion Rheumotol 1998 ; 10:669-76.
14. Plows D, Probert L, Gerogopoulos S, Alexopoulou L, Kolias G. The role ol tumour necrosis factor (TNF) in arthritis studies in transgenic mice. Rheumotol Europe 1995 ; suppl 2:51-4.
15. Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992 ; 89:244-50.
16. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumour necrosis factor α and transforming growth factor ß during induction of collagen type II arthritis in mice Proc Natl Acad Sci USA 1992 ; 89:7375-9.
17. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates pint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992 ; 89:978-88.
18. Williams RO, Ghrayeb J, Feldmann M, Maini RN. Successful therapy of collagen-induced arthritis with TNF receptor IgG fusion protein and combination with antiCD4 Immunology 1995 ; 84:433-9.
19. Tetta C, Camussi G, Modena V, DiVittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990 ; 49:665-7.
20. Brooks PM. The Heberden oration 1997 treatment of rheumatoid arthritis: from symptomatic relief to potential cure. Brit J Rheumatal 1998 ; 37:1265-71.
21. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991 ; 34:1125-32.
22. Jorgensen C, Couret I, Canovas F et al. Mononudear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is upregulated by tumour necrosis factor-alpha (TNFα) and mediated through intercellular adhesion molecule-1 (ICAM-1 ).Clin Exp Immunol 1996; 106:20-5.
23. Deleuran BW, Chu CQ, Field M et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 1992 ; 35:1170-8.
24. Li JM, Isler P. Dayer JM, Burger D. Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-Cell dones. Immunology 1995 ; 84:571-75.
25. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18:187-92.
26. Wallis W, Furst DE, Strand V, Keystone E. Biologic agents and immunotherapy in rheumatoid arthritis. Rheum Dis Clin North Am ) 998 ; 24:537-65.
27. Davis D, Elliott MJ, Maini RN. The clinical application of cytokine blockade in the therapy of rheumatoid arthritis. In: Therapy of systemic rheumatic disorders. Van de Putte LBA, Furst DE, Williams HJ, Van Riel PLCM eds Marcel Dekker Inc, New York 1998: 299-315
28. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993 ; 36:1681-90.
29. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 ; 344:1105-10.
30. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344:1125-7.
31. Lipsky P., St. Clair W, Kavanaugh A et al. Long-term control of signs and symptoms of rheumatoid arthritis with chimeric monodonal anti-TNFα antibody (Infliximab) in patients with active disease on methotrexate. Arthritis Rheum 1998 ; 41(suppl. 9) 1988:5364.
32. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intra venous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate n rheumatoid arthritis. Arthritis Rheum 1998 ; 41:1552-63.
33. Rankin ECC, Choy EHS, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571 ) in rheumatoid arthritis. Br J Rheumatol 1995 ; 34:334-42.
34. Rau R, Sander O, den Breeder A et al. Long-term efficacy and tolerability of multiple IV doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998 ; 41(suppl. 9), 137:555.
35. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by antiturror necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 59:1077-81.
36. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor a necrosis factor antibody in rheumatoid arthritis. Arthritis Rheum 1996 ; 59:1082-91.
37. Vaes G. Protéinases cellulaires et leurs inhibiteurs. In: l'Inflammation. Russo Mane F, Peltier A Polla B eds. John libbey Eurotext, Paris 1998:317-33.
38. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalioproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor α (cA2) therapy. Br J Rheumatol 1997 ; 36:643-50.
39. Perkins DJ, St. Clair EW, Misukonis MA, Weinberg JB. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor a monoclonal antibody (cA2). Arthritis Rheum 1998 ; 41:2205-10.
40. Lorenz HM, Antoni C, Valerius T et al. In vivo blockade of TNFα by intravenous infusion of a chimeric monoclonal TNFα antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996 ; 156:1646-53.
41. Taylor PC, Chapman P, Elliott MJ et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy. Arthritis Rheum 1997 ; 40(suppl.)297:S80.
42. Moreland LW, Margolies G, Heck LW Jr et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996 ; 25:1849-55.
43. Moreland LW, Baumgartner SW, Schiff MH el al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 ; 337:141 -7.
44. Kavanaugh A, Heudebert G, Cush J, Jain R. Cost evaluation of novel therapeutics in rheumatoic arthritis (CENTRA): a decision analysis modei. Semin Arthritis Rheum 1996 ; 75:297-307.
45. McKay J, Rau R, Weisman M et al. A double-blind, randomized, 6 arm, parallel-group, dose finding, double-dummy, multi-center comparison of sTNF r55 IgG (Ro 45 2081 lenercept (LEN)) subcutaneous (sc) to reference treatment with oral methotrexate (MTX) and their combination in patients with rheumatoid arthritis (RA) (12 week dose-finding efficacy / safety study). Arthritis Rheum 1998 ; 41 (suppl. 9)595:S132.
46. Weinblatt ME, Kremer JM, Bankhurst AD et al. Phase II/III trial of TNF receptor p75 Fc fusion proteins (TNF: Fc, Enbrei®)) in combination with methotrexate (MTX) in RA patients, arthritis Rheum 1998 ; 41(suppl 9) 939:S189.
47. Rothe J, Lesslauer W, Lȯtscher H et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993 ; 564:798-802.
48. Akerlund K, Erlandsson Harris H, Tracey KJ et al. Antiinflammatory effects of a new tumour necrosis factor-alpha (TNFα) innibitor (CNI-1493) n collagen-induced arthntis (CIA) in rats. Clim Exp Immunol 1999 ; 115:32-41.
49. Chary-Walckenaere I, Porumb H, Taillandier E, Pourel J. Oligonucleotides: a new resource in rheumatology ? Rev Rhum 1998 ; 65:543-5.
50. Evans CH, Ghivizzani SC, Kang R et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999 ; 49:1-16.